PUBLISHER: The Business Research Company | PRODUCT CODE: 1955452
PUBLISHER: The Business Research Company | PRODUCT CODE: 1955452
Huoxiang Zhengqi for COVID-19 is a traditional Chinese herbal formula used to manage COVID-19 cases, especially when symptoms include gastrointestinal issues such as nausea, diarrhea, or fatigue caused by dampness. Its primary role is to expel dampness, relieve exterior syndromes, and support digestive and immune function. It is often used alongside antiviral and supportive therapies in traditional Chinese medicine protocols.
The main types of Huoxiang Zhengqi for COVID-19 include liquids, pills, granules, and other forms. Huoxiang Zhengqi liquid is designed to relieve digestive symptoms such as nausea, vomiting, and bloating by restoring balance to the stomach and spleen. Its users typically include health-conscious individuals, those seeking immune support, alternative medicine enthusiasts, and parents purchasing for their children. It is commonly applied for preventive health, symptom management during COVID-19, post-recovery care, and seasonal or illness-related protection. The product is used in hospitals, clinics, home care settings, and other healthcare environments.
Tariffs have affected the huoxiang zhengqi for covid 19 market by increasing the cost of imported herbal raw materials, botanical extracts, and packaging components used in traditional formulations. These impacts have been most visible in liquid and granule product segments, particularly in export-driven Asia-Pacific markets. International distribution channels have faced pricing volatility due to trade barriers. However, tariffs have encouraged domestic cultivation of medicinal herbs and localized production, strengthening supply stability.
The huoxiang zhengqi for covid 19 market research report is one of a series of new reports from The Business Research Company that provides huoxiang zhengqi for covid 19 market statistics, including huoxiang zhengqi for covid 19 industry global market size, regional shares, competitors with a huoxiang zhengqi for covid 19 market share, detailed huoxiang zhengqi for covid 19 market segments, market trends and opportunities, and any further data you may need to thrive in the huoxiang zhengqi for covid 19 industry. This huoxiang zhengqi for covid 19 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The huoxiang zhengqi for covid 19 market size has grown rapidly in recent years. It will grow from $1.54 billion in 2025 to $1.73 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to high reliance on traditional medicine during health crises, government endorsement of TCM during covid-19, limited early pharmaceutical options, cultural preference for herbal remedies, rapid demand during pandemic waves.
The huoxiang zhengqi for covid 19 market size is expected to see rapid growth in the next few years. It will grow to $2.72 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to continued interest in immune-support therapies, expansion of integrative medicine practices, rising health-conscious consumer base, growth of herbal pharmaceutical manufacturing, increasing research into traditional formulations. Major trends in the forecast period include growing acceptance of traditional chinese medicine, increasing use of herbal formulations for immune support, expansion of preventive healthcare applications, rising integration with conventional covid therapies, increasing demand for digestive and immune health remedies.
The rising demand for herbal medicine is expected to drive the growth of the Huoxiang Zhengqi for COVID-19 market in the coming years. Herbal medicine involves the use of plants or plant-derived substances for therapeutic purposes to prevent, treat, or manage health conditions. This growing demand is largely fueled by consumers' preference for natural, plant-based remedies over synthetic drugs, due to perceived safety, fewer side effects, and holistic health benefits. Huoxiang Zhengqi for COVID-19 supports herbal medicine by offering a traditional remedy that enhances immune function, alleviates symptoms, and promotes recovery, highlighting the potential of herbal therapies in managing viral infections. For example, in September 2024, HerbalGram, a US-based nonprofit organization, reported that total annual sales of herbal dietary supplements increased from $12.018 billion in 2022 to $12.551 billion in 2023, reflecting a 4.4% growth. Consequently, the growing demand for herbal medicine is propelling the expansion of the Huoxiang Zhengqi for COVID-19 market.
Leading companies in the Huoxiang Zhengqi for COVID-19 market are focusing on innovative private-brand product launches, such as Huoxiang Zhengqi oral liquid formulations. These modernized liquid versions of the traditional Huoxiang Zhengqi herbal formula are designed to enhance convenience, ensure accurate dosing, and promote faster absorption. For example, in June 2024, YSB Inc., a China-based pharmaceutical retail and healthcare services company, launched the Leyaoshi Huoxiang Zhengqi Oral Liquid. The product features a ready-to-drink, single-dose liquid format, provides rapid digestive and anti-dampness support, and has a formulation optimized for seasonal gastrointestinal discomfort.
In August 2024, China Resources Sanjiu, a China-based provider of traditional Chinese medicines and pharmaceutical products, acquired a 28% stake in Tasly Pharmaceuticals for USD 8.75 billion (RMB 62.12 billion). This acquisition was intended to strengthen the company's control over Tasly, enhancing its strategic capabilities in modern Chinese medicine innovation and integrated drug development. Tasly Pharmaceuticals is a China-based company specializing in modern traditional Chinese medicines, chemical drugs, and biopharmaceutical therapies.
Major companies operating in the huoxiang zhengqi for covid 19 market are Yunnan Baiyao Group Co. Ltd., Beijing Tongrentang Co. Ltd., Taiji Group Chongqing Fuling Pharmaceutical Factory Co. Ltd., Tasly Pharmaceutical Group Co. Ltd., Harbin Pharmaceutical Group Co. Ltd., Guizhou Sanli Pharmaceutical Co. Ltd., China Shineway Pharmaceutical Group Limited, Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., Wuhu Zhanghengchun Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd., Sichuan Neo-Green Pharmaceutical Technology Co. Ltd., Hutchison China MediTech Limited, Shijiazhuang Yiling Pharmaceutical Co. Ltd., Jilin Aodong Pharmaceutical Group Co. Ltd., Livzon Pharmaceutical Group Inc., China Traditional Chinese Medicine Holdings Co. Ltd., Kunming Pharmaceutical Corp., Guangdong Yifang Pharmaceutical Co. Ltd., Jiangyin Tianjiang Pharmaceutical Co. Ltd.
Asia-Pacific was the largest region in the Huoxiang Zhengqi for COVID-19 market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the huoxiang zhengqi for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the huoxiang zhengqi for covid 19 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The huoxiang Zhengqi for COVID-19 market consists of sales of syrups, powders, injections, essential oils, and nasal sprays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Huoxiang Zhengqi For Covid 19 Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses huoxiang zhengqi for covid 19 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for huoxiang zhengqi for covid 19 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The huoxiang zhengqi for covid 19 market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.